cancer treatment
Advertisement
Janssen Pharmaceuticals has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...
Lurbinectedin may be a viable option as a second-line treatment for small-cell lung cancer (SCLC) patients whose ...
A new study has found that patients with non-small cell lung cancer (NSCLC) and kidney cancer may benefit from ...
Early treatment with the anaplastic lymphoma kinase (ALK)-inhibitor lorlatinib reduced cancer progression and death in ...
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.